NCT02052986View on ClinicalTrials.gov

An Open-Label Study of Vascazen in Cardiac Rehab Patients With Deficient Blood Omega-3 Fatty Acid Levels

PHASE2UnknownINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

Not specified

Primary Completion Date

January 31, 2015

Conditions

Dyslipidemia

Interventions

OTHER

VASCAZEN

All enrolled subjects will receive 4 capsules daily of VASCAZEN which delivers 3.0 grams of EPA and DHA

Trial Locations (1)

11365

The NYHQ Cardiac Health Center, Fresh Meadows

Sponsors

Collaborators (1)

Pivotal Therapeutics

All Listed Sponsors

collaborator

NYHQ Cardiac Health Center

UNKNOWN

collaborator

Pivotal Therapeutics

UNKNOWN

lead

New York Hospital Queens

OTHER